FMC to Explore Strategic Alternatives Including Possible Sale

Dow Jones02-05 06:33

By Kelly Cloonan

FMC plans to explore strategic options for the company, including a potential sale.

The agricultural sciences company said Wednesday the strategic review is at a preliminary stage, and it cannot be certain that any transaction will occur.

FMC continues to focus on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements, the company said, including the sale of its commercial business in India.

The company is also working to improve the competitiveness of its legacy core portfolio and manage its Rynaxypyr product after its patent expired. It will also continue advancing commercialization for new active ingredients.

The company said it believes additional investment in its four new active ingredients might accelerate growth and improve its results.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

February 04, 2026 17:33 ET (22:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609311384?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609311384","market":"sg","top_or_hot":-1,"title":"FMC to Explore Strategic Alternatives Including Possible Sale","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  FMC plans to explore strategic options for the company, including a potential sale. \n</p>\n<p>\n  The agricultural sciences company said Wednesday the strategic review is at a preliminary stage, and it cannot be certain that any transaction will occur. \n</p>\n<p>\n  FMC continues to focus on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements, the company said, including the sale of its commercial business in India. \n</p>\n<p>\n  The company is also working to improve the competitiveness of its legacy core portfolio and manage its Rynaxypyr product after its patent expired. It will also continue advancing commercialization for new active ingredients. \n</p>\n<p>\n  The company said it believes additional investment in its four new active ingredients might accelerate growth and improve its results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 17:33 ET (22:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FMC to Explore Strategic Alternatives Including Possible Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFMC to Explore Strategic Alternatives Including Possible Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-05 06:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  FMC plans to explore strategic options for the company, including a potential sale. \n</p>\n<p>\n  The agricultural sciences company said Wednesday the strategic review is at a preliminary stage, and it cannot be certain that any transaction will occur. \n</p>\n<p>\n  FMC continues to focus on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements, the company said, including the sale of its commercial business in India. \n</p>\n<p>\n  The company is also working to improve the competitiveness of its legacy core portfolio and manage its Rynaxypyr product after its patent expired. It will also continue advancing commercialization for new active ingredients. \n</p>\n<p>\n  The company said it believes additional investment in its four new active ingredients might accelerate growth and improve its results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 17:33 ET (22:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2609311384","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609311384","pubTimestamp":1770244380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"FMC plans to explore strategic options for the company, including a potential sale.The agricultural sciences company said Wednesday the strategic review is at a preliminary stage, and it cannot be certain that any transaction will occur.FMC continues to focus on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements, the company said, including the sale of its commercial business in India.The company is also working to improve the competitiveness of its legacy core portfolio and manage its Rynaxypyr product after its patent expired. It will also continue advancing commercialization for new active ingredients.The company said it believes additional investment in its four new active ingredients might accelerate growth and improve its results.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","LU0385154629.USD":"贝莱德营养科学基金A2","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4545":"锂电池","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","FMC":"FMC Corp."},"translate_title":"FMC将探索战略替代方案，包括可能的出售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMC":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  FMC plans to explore strategic options for the company, including a potential sale. \n\n\n  The agricultural sciences company said Wednesday the strategic review is at a preliminary stage, and it cannot be certain that any transaction will occur. \n\n\n  FMC continues to focus on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements, the company said, including the sale of its commercial business in India. \n\n\n  The company is also working to improve the competitiveness of its legacy core portfolio and manage its Rynaxypyr product after its patent expired. It will also continue advancing commercialization for new active ingredients. \n\n\n  The company said it believes additional investment in its four new active ingredients might accelerate growth and improve its results. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 17:33 ET (22:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609311384","isCrawlerRequest":true}